Women As Monaco Basketball Jersey, 215 N Center San Antonio, Articles F

Home Publications NCI Dictionaries NCI Dictionary of Cancer Terms Form FDA 1572-Statement of Investigator (. Form FDA 3674 %%EOF Form FDA 3926 In 2019, signing the Form FDA 1572 was even deemed illegal and in certain European countries like Germany, EU GCP inspectors prohibited the completion of this form. This form is designed specifically for single patient IND requests. These cookies will be stored in your browser only with your consent. The process owner would also be required to communicate with regulators and industry experts to keep apprised of new regulations, guidances, and best practices. xMK@NT((cSZb-2fgy |1GD$"*{gI2'C^=1p 1(u5DQ0Wn&y)).a}N[Gy\WHfGl*u.X`ZRs-ie^:'a!vQFg\!Z|Ysm8zIfM[#t2: E"-7znf*j /+7_U5epM_QI!E An official website of the United States government, : The Food and Drug Administration (FDA or agency) has received a number of questions about Form FDA. Form FDA 1571: Coversheet for all IND submissions. Interested in learning about current topics concerning FDA regulated research? endobj Form FDA 1572 - Statement of Investigator - Docest A website protected by SSL certificate is also a more efficient website from a marketing point of view. Form FDA 3674. Decisions, Decisions: Complete 1572 Or Alternate Process? Software that can guarantee the existence of your digital documents or files on a given date and time. (a) Progress reports. Customized electronic signature modules that are fully integrated into your information system. The sponsor shall obtain a commitment from the clinical investigator to promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. Necessary cookies are absolutely essential for the website to function properly. The cookie is used to store the user consent for the cookies in the category "Performance". FDA now offering Form FDA 1572 waivers - Hogan Lovells The letter of authorization should include relevant identifying information, such as the sponsors relevant application (e.g., IND) number. Draft Information Sheet Guidance for Sponsors, Clinical Investigators PAGE 2 OF 2. The second option has more requirements, including more resources to ensure compliance. When I get an answer, Ill be sure to update my readers, of course! This form should be sent with DocuSign's, " below. To understand: What the purpose of Form FDA 1572 is. Before permitting an investigator to begin participation in an investigation, the sponsor shall obtain the following: (1) A signed investigator statement (Form FDA-1572) containing: Certification of Compliance, Instructions for completing The commitment to a single SAP should also be stated. endstream endobj startxref endobj 5 0 obj The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. In removing these types of barriers, both organisations focus on conducting research, much more efficiently, which will be beneficial to cancer patients.. Center for Biologics Evaluation and Research, An official website of the United States government, : In the second option, the sponsor performs a global trial including all clinical sites (U.S.- or non-U.S.-based) performed under the IND. stream The commitments the investigator agrees to by signing Form FDA 1572. FDA Releases Draft Guidance about Form FDA 1572 | CITI Program NOTE: 339 0 obj <>stream When you submit your request you will need to provide a statement that states that informed consent and approval of the use by an appropriate Institutional Review Board (IRB) will be obtained prior to initiating treatment. This cookie is set by GDPR Cookie Consent plugin. Based on the rules and regulations of the FDA, in completing form FDA 1572, the statement of the investigator, the investigator agrees to follow the U.S. Food and Drug Administration (FDA) Code of Federal Regulations for the clinical trial. 4 0 obj The .gov means its official.Federal government websites often end in .gov or .mil. an investigator is participating in a new protocol which is added to an active IND; 2.) They should also include a statement of commitment on an alternate, signed form or on the protocol signature page. FDA developed this draft information sheet guidance in response to numerous questions from the research community regarding Form FDA 1572. %PDF-1.6 % Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. A curriculum vitae or other statement of qualifications of the investigator showing the education, training, and experience that qualifies the investigator as an expert in the clinical investigation of the drug for the use under investigation. CFR - Code of Federal Regulations Title 21 - Food and Drug Administration STAYT-ment in-VES-tih-GAY-ter) A form that must be filed by an investigator running a clinical trial to study a new drug or agent. Template Library: Statement of Investigator, FDA 1572. Template Library: Statement of Investigator, FDA 1572 Language Assistance Available: Espaol | | Ting Vit | | Tagalog | | | Kreyl Ayisyen | Franais | Polski | Portugus | Italiano | Deutsch | | | English, The information on this page is current as of. I have heard questions about the form in local and international forums, and a question about it was directed at the FDA (but not addressed) at a regulatory conference. The protocol should be submitted as an IND amendment (either global or U.S.-based only) and include notification that non-IND sites will also contribute data. What are the minimum qualifications of an investigator? (g ) Will ensure that all associates, colleagues, and employees assisting in the conduct of the study(ies) are informed about their obligations in meeting the above commitments. It describes how to complete the Statement of Investigator form (Form FDA 1572). A sponsor shall ship investigational new drugs only to investigators participating in the investigation. NOTE: No investigator may participate in an investigation until he/she provides the sponsor with a completed, signed Statement of Investigator, Form FDA 1572 (21 CFR 312.53(c)). The site is secure. MedWatch: The FDA Safety Information and Adverse Event Reporting Program - Mandatory The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. the Principal Investigator of an ongoing study changes, or 3.) May 16, 2022 The FDA's Good Clinical Practice Program (GCPP) fields dozens of questions each year related to completing and signing the Form FDA 1572 Statement of Investigator. Get more clinical research insight with our FREE newsletter, https://www.bobdylan.com/songs/times-they-are-changin/, https://www.centerwatch.com/news-online/2017/07/24/attractiveness-conducting-clinical-trials-outside-u-s/, https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM074728.pdf, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=312, https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM223432.pdf, https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2014_536/reg_2014_536_en.pdf, https://laegemiddelstyrelsen.dk/en/licensing/clinical-trials/gcp-inspection/clinical-trials-under-us-legislation/, http://eaquality.org/news/37-fda-1572-in-germany.html, https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM214282.pdf, https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM294729.pdf. (2) Curriculum vitae. On this page, you will find information about completing Form FDA 1571 and Form FDA 1572. Importantly, EU regulators have cited non-U.S. sites for having completed the 1572 with or without the full documentation of the discrepancies and associated waiver. Form FDA 3674: Certification of the Requirement to post the trial on clinicaltrials.gov. Therefore, the regulatory procedures need to be addressed when clinical trials are conducted in different territories. Frequently Asked Questions: Statement of Investigator (Form FDA 1572) Form FDA 3926: A single-patient IND expanded access request thatallows for IRB chairperson concurrence rather than full board review. <>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 720 540] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> What is the FDA Form 1572? In completing form fda 1572, statement of investigator, the Due to aggressive automated scraping of FederalRegister.gov and eCFR.gov, programmatic access to these sites is limited to access to our extensive developer APIs. Form FDA 1572 - Statement of Investigator 1 2 DEP ARTMENT OF HEAL TH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRA TION ST A TEMENT OF INVESTIGA T OR (TITLE 21, CODE OF FEDERAL REGULA TIONS (CFR) P ART 312) (See instructions on reverse side.) Use DocuSign eSignature to easily upload and send documents for electronic signature from anywhere and on any device. IND Forms and Instructions | FDA One of the keys to ensure compliance at the sponsor level is the creation, management, and enforcement of process documentation in the form of an SOP. Form FDA 1571 and 1572 are still required for other expanded access submissions (e.g., intermediate access or treatment INDs) and for IND submissions by commercial sponsors or drug manufacturers. In May 2021, the U.S. Food and Drug Administration (FDA) published a draft guidance (Draft Guidance) addressing the requirement for all investigators involved in clinical trials conducted under a U.S. Investigational New Drug (IND) application to sign Form FDA 1572. new 1572 is required when any one of the following conditions apply: 1.) Form FDA 1572:Statement of Investigator. You will need to provide the FDA with the a statement that specifies the training, experience, and licensure of the treating physician. The cookies store information anonymously and assign a randomly generated number to identify unique visitors. (Device studies require similar information -although not exactly the same -and no standard form: 21 CFR 812.100. The 1571 must be signed by the Sponsor of the IND. A passionate advocate for moving life sciences business online, Betsy is an expert on many areas of drug development. Search for FDA Guidance Documents, Recalls, Market Withdrawals and Safety Alerts, Search General and Cross-Cutting Topics Guidance Documents, Decentralized Clinical Trials for Drugs, Biological Products, and Devices, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers, Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products, Clinical Investigator Administrative Actions Disqualification, Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment, Tissue Agnostic Drug Development in Oncology, Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials, Ethical Considerations for Clinical Investigations of Medical Products Involving Children, Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations, Investigator Responsibilities Safety Reporting for Investigational Drugs and Devices, Sponsor ResponsibilitiesSafety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies Guidance for Industry, Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1), Enhancing the Diversity of Clinical Trial Populations Eligibility Criteria, Enrollment Practices, and Trial Designs, Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank, Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological ProductsContent and Format, Conduct of Clinical Trials of Medical Products during COVID19 Public Health Emergency, Providing Regulatory Submissions in Electronic Format Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, Adaptive Design Clinical Trials for Drugs and Biologics, Postmarketing Studies and Clinical Trials - Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act, Humanitarian Device Exemption (HDE) Program, Humanitarian Use Device (HUD) Designations, ICH E8(R1): General Considerations for Clinical Studies, Clinical Lactation Studies: Considerations for Study Design, Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers, Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials, Impact of Certain Provisions of the Revised Common Rule on FDARegulated Clinical Investigations, ICH E17: General Principles for Planning and Design of MultiRegional Clinical Trials, Institutional Review Board (IRB) Written Procedures, ICH E11(R1): Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population, Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials, ICH E6(R2): Good Clinical Practice: Integrated Addendum to ICH E6(R1), Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions, Payment and Reimbursement to Research Subjects, Investigational IVDs Used in Clinical Investigations of Therapeutic Products, Waiver of IRB Requirements for Drug and Biological Product Studies, Individual Patient Expanded Access Applications: Form FDA 3926, Minutes of Institutional Review Board (IRB) Meetings, Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies, IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects, Use of Electronic Records and Electronic Signatures in Clinical Investigations Under 21 CFR Part 11 Questions and Answers, Form FDA 3674 Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions, Emergency Use Authorization of Medical Products and Related Authorities, Use of Electronic Informed Consent in Clinical Investigations Questions and Answers, Clinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes, Collection of Race and Ethnicity Data in Clinical Trials, Adaptive Designs for Medical Device Clinical Studies, Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information, Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices, Charging for Investigational Drugs Under an IND Questions and Answers, Expanded Access to Investigational Drugs for Treatment Use Questions and Answers, Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails, Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products Content and Format Guidance for Industry (Small Entity Compliance Guide), Evaluation of Sex-Specific Data in Medical Device Clinical Studies, Considerations When Transferring Clinical Investigation Oversight to Another IRB, Meaning of "Spouse" and "Family" in FDA's Regulations after the Supreme Court's Ruling in United States v. Windsor: Questions and Answers, Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only, Design Considerations for Pivotal Clinical Investigations for Medical Devices, Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies, Electronic Source Data in Clinical Investigations, Investigational New Drug Applications (INDs) Determining Whether Human Research Studies Can Be Conducted Without an IND, IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed, Oversight of Clinical Investigations A Risk-Based Approach to Monitoring, Exception from Informed Consent Requirements for Emergency Research, Financial Disclosure by Clinical Investigators, ICH E3: Structure and Content of Clinical Study Reports, Questions and Answers, Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies, Safety Reporting Requirements for INDs and Bioavalability/Bioequivalence (BA/BE) Studies Small Entity Compliance Guide, FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions, ICH E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers, IRB Continuing Review After Clinical Investigation Approval, Informed Consent Elements, 21 CFR 50.25(c), Questions and Answers, Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application, In Vitro Diagnostic (IVD) Device Studies Frequently Asked Questions, Statement of Investigator (Form FDA 1572) Frequently Asked Questions, FDA Inspections of Clinical Investigators, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects, IRB Registration Frequently Asked Questions, Adverse Event Reporting to IRBs Improving Human Subject Protection, Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices, Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials, Current Good Manufacturing Practice for Phase 1 Investigational Drugs, Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions, Computerized Systems Used in Clinical Investigations, Process for Handling Referrals to FDA Under 21 CFR 50.54 Additional Safeguards for Children in Clinical Investigations, ICH E5 Ethnic Factors in the Acceptability of Foreign Clinical Data, Questions and Answers, Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable, Establishment and Operation of Clinical Trial Data Monitoring Committees, Using a Centralized IRB Review Process in Multicenter Clinical Trials, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products Content and Format, Medical Devices Frequently Asked Questions, Significant Risk and Nonsignificant Risk Medical Device Studies, FDA Institutional Review Board Inspections, Development and Use of Risk Minimization Action Plans, Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, Use of Clinical Holds Following Clinical Investigator Misconduct, Independent Consultants for Biotechnology Clinical Trial Protocols, Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples, Financial Conflict of Interest: HHS Guidance (2004), IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer, Part 11, Electronic Records; Electronic Signatures Scope and Application, IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations, INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information, Food-Effect Bioavailability and Fed Bioequivalence Studies, General Principles of Software Validation, ICH E10: Choice of Control Group and Related Issues in Clinical Trials, ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population, Clinical Holds Submitting and Reviewing Complete Responses, Categories of Research That May Be Reviewed Through an Expedited Review Process, ICH E5: Ethnic Factors in the Acceptability of Foreign Clinical Data, Evaluation of Gender Differences in Clinical Investigations, Institutional Review Boards Frequently Asked Questions, Sponsor-Investigator-IRB Interrelationship, Screening Tests Prior to Study Enrollment, Use of Investigational Products When Subjects Enter a Second Institution, Off-Label and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices, Emergency Use of an Investigational Drug or Biologic, Clinical Investigator Regulatory Sanctions Information Sheet, ICH E8: General Considerations for Clinical Trials, Design Control Guidance For Medical Device Manufacturers, ICH E3: Structure and Content of Clinical Study Reports, ICH E7: Studies in Support of Special Populations: Geriatrics, Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, Clinical Trials and Human Subject Protection, Electronic Code of Federal Regulations (eCFR), Websites with Information about Clinical Trials, Real World Data/Real World Evidence (RWD/RWE), Disqualification, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigator, Inspection, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigator, 1572, HIPAA, Human Subject Protection (HSP), Investigation, Design, Diversity, Ethics Committee (EC), Ethnicity, Gender, Good Clinical Practice (GCP), Human Subject Protection (HSP), Civil Money Penalties, clinicaltrials.gov, Design, Investigation, Labeling, Lactation, Pregnancy, Sponsor, Coronavirus, COVID, Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigation, Electronic, Investigational New Drug (IND), Part 11, Records, Design, Good Clinical Practice (GCP), Investigation, Sponsor, Clinical Medical, Design, Good Clinical Practice (GCP), Investigation, Sponsor, Bioavailability, design, drug safety, good clinical practice, investigation, postmarketing, Exemption, Humanitarian Device Exemption (HDE), Humanitarian Use Device (HUD), Medical Device, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Records, Sponsor, Design, Investigation, Lactation, Sponsor, Clinical, Design, Efficacy, Variability, Protocol, Exclusion, Inclusion, Genomic, Children, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Pediatric, Common Rule, Human Subject Protection (HSP), Institutional Review Board (IRB), Design, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Records, Sponsor, Institutional Review Board (IRB), Records, Children, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Records, Sponsor, Gender, Human Subject Protection (HSP), Institutional Review Board (IRB), Investigation, Pregnancy, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Sponsor, Good Clinical Practice (GCP), Investigation, Investigational Device Exemption (IDE), Medical Device, Human Subject Protection (HSP), Informed Consent, Good Clinical Practice (GCP), In Vitro Diagnostic (IVD), Investigation, Investigational Device Exemption (IDE), Investigational New Drug (IND), Labeling, Medical Device, Sponsor, Human Subject Protection (HSP), Institutional Review Board (IRB), Waiver, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigation, Investigational New Drug (IND), Demographic, Diversity, Ethnicity, Gender, Investigation, Medical Device, Pediatric, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Waiver, Good Clinical Practice (GCP), Human Subject Protection (HSP), Electronic, Investigation, Part 11, Records, Certify, Certification, clinicaltrials.gov, Medical Device, Emergency, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigation, Investigational New Drug (IND), Electronic, Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Part 11, Records, Advisory Committees, Clinical Medical, Good Clinical Practice (GCP), Humanitarian Device Exemption (HDE), Humanitarian Use Device (HUD), Labeling, Laser Notice, Medical Device, Neurological, Premarket, Premarket Approval (PMA), Safety, Sponsor, Good Clinical Practice (GCP), Humanitarian Device Exemption (HDE), Humanitarian Use Device (HUD), Investigational Device Exemption (IDE), Medical Device, Premarket, Premarket Approval (PMA), Sponsor, 510k, Chemistry Manufacturing Controls (CMC), Good Clinical Practice (GCP), Investigation, Sponsor, Children, Human Subject Protection (HSP), Medical Device, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Demographic, Design, Gender, Good Clinical Practice (GCP), Medical Device, Premarket, Sponsor, Informed Consent, Institutional Review Board (IRB), In Vitro, Investigation, Medical Device, Specimen, Design, Good Clinical Practice (GCP), Investigation, Medical Device, Premarket, Sponsor, Institutional Review Board (IRB), Investigation, Medical Device, Safety, Good Clinical Practice (GCP), Electronic, Part 11, Records, Institutional Review Board (IRB), Investigation, Investigational New Drug (IND), Institutional Review Board (IRB), Investigational Device Exemption (IDE), Investigational New Drug (IND), Investigator, Medical Device, Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Financial Disclosure, Good Clinical Practice (GCP), Good Clinical Practice (GCP), International Conference on Harmonization (ICH), Sponsor, Bioavailability, Bioequivalence, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Safety, Design, Diversity, Ethnicity, Gender, International Conference on Harmonization (ICH), Sponsor, Continuing Review, Institutional Review Board (IRB), Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigational New Drug (IND), Human Subject Protection (HSP), In Vitro, Informed Consent, Medical Device, Specimen, Good Clinical Practice (GCP), Human Subject Protection (HSP), Inspection, Investigator, Investigation, Investigational New Drug (IND), Product Development, Clinical Investigator, Institutional Review Board (IRB), Institutional Review Board (IRB), Registration, Institutional Review Board (IRB), Report, Safety, Drug, Labeling, Practice, Medical Device, Medicine, Sponsor, Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Investigation, In Vitro Diagnostic (IVD), Laboratory Developed Test (LDT), Medical Device, Reagent, Children, Human Subject Protection (HSP), Informed Consent, Institutional Review BA/BEoard (IRB), Pediatric, Design, Diversity, Ethics Committee (EC), Ethnicity, Gender, Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Sponsor, Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), Institutional Review Board (IRB), Multicenter, Single, Institutional Review Board (IRB), Medical Device, Risk, Safety, Human Subject Protection (HSP), Institutional Review Board (IRB), Inspection, Good Clinical Practice (GCP), Investigational New Drug (IND), Risk, Safety, Clinical Medical, Good Clinical Practice (GCP), Good Clinical Practice (GCP), Hold, Investigation, Investigational New Drug (IND), Investigator, Misconduct, Financial Disclosure, Good Clinical Practice (GCP), Institutional Review Board (IRB), Exemption, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Electronic, Good Clinical Practice (GCP), Part 11, Records, Chemistry Manufacturing Controls (CMC), Investigation, Investigational New Drug (IND), Sponsor, Bioavailability, Bioequivalence, Drug, Food, Investigational New Drug (IND), Electronic, Investigation, Medical Device, Part 11, Quality, Risk, Software, Validation, Good Clinical Practice (GCP), Hold, Investigation, Investigational New Drug (IND), Investigator, Expedited Review, Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), Design, Diversity, Ethics Committee (EC), Ethnicity, Gender, International Conference on Harmonization (ICH), Sponsor, Demographic, Gender, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigation, Investigational New Drug (IND), Human Subject Protection (HSP), Institutional Review Board (IRB), Good Clinical Practice (GCP), Institutional Review Board (IRB), Investigator, Sponsor, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Medical Device, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Recruit, Recruitment, Human Subject Protection (HSP), Informed Consent, Recruit, Recruitment, Human Subject Protection (HSP), Informed Consent, Investigation, Investigational Device Exemption (IDE), Investigational New Drug (IND), Institutional Review Board (IRB), Medical Device, Investigation, Investigational New Drug (IND), Medical Device, Practice of Medicine, Emergency, Human Subject Protection (HSP), Informed Consent, Investigational New Drug (IND), Institutional Review Board (IRB), Human Subject Protection (HSP), Investigation, Investigational New Drug (IND), Institutional Review Board (IRB), Design, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Sponsor, Good Clinical Practice (GCP), Investigator, Sanction, Design, Good Manufacturing Practice (GMP), Medical Device, Sponsor, Ethics Committee (EC), Design, Diversity, Ethnicity, Gender, Human Subject Protection (HSP), International Conference on Harmonization (ICH), Sponsor.